Cancer Lett

1. FENG X, Ji Z, Fan X, Kong Y, et al
   ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
   Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
   

   >> Share

   
   

   
   Gynecol Oncol

2. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
   Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
   Gynecol Oncol. 2024;188:60-70.
   

   >> Share

   
   
3. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
   Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
   Gynecol Oncol. 2024;188:58-59.
   

   >> Share

   
   

   
   Int J Gynaecol Obstet

4. ALIABADI AR, Wilailak S, McNally O, Berek JS, et al
   Contraceptive strategies for reducing the risk of reproductive cancers.
   Int J Gynaecol Obstet. 2024 May 9. doi: 10.1002/ijgo.15567.
   

   >> Share

   
   

   
   Oncogene

5. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
   TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
   Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
   

   >> Share

   
   

   
   PLoS One

6. JANG DH, Lee HG, Lee B, Kang S, et al
   Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study.
   PLoS One. 2024;19:e0305360.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share